History of COVID-19 vaccine development (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "History of COVID-19 vaccine development" in English language version.

refsWebsite

Global rank English rank

133web.archive.org

1^st place

46nih.gov

4^th place

37europa.eu

68^th place

117^th place

30doi.org

2^nd place

10worldcat.org

5^th place

8nytimes.com

7^th place

8who.int

195^th place

302^nd place

8tga.gov.au

3,984^th place

2,622^nd place

6harvard.edu

18^th place

17^th place

6semanticscholar.org

11^th place

8^th place

6gov.uk

432^nd place

278^th place

6bbc.com

20^th place

30^th place

4fda.gov

447^th place

338^th place

4cdc.gov

218^th place

212^th place

4reuters.com

49^th place

47^th place

3statnews.com

8,771^st place

5,253^rd place

3cnn.com

28^th place

26^th place

2scmp.com

362^nd place

245^th place

2globalnews.ca

985^th place

583^rd place

2canada.ca

1,712^th place

1,063^rd place

2nbcnews.com

137^th place

101^st place

2telegraph.co.uk

30^th place

24^th place

2bloomberg.com

99^th place

77^th place

2theguardian.com

12^th place

11^th place

2admin.ch

279^th place

551^st place

1hbr.org

2,754^th place

1,686^th place

1cbc.ca

115^th place

82^nd place

1theconversation.com

928^th place

651^st place

1youtube.com

9^th place

13^th place

1pfizer.com

low place

1time.com

61^st place

54^th place

1bna.bh

low place

1gulfnews.com

765^th place

523^rd place

1cnbc.com

220^th place

155^th place

1tass.ru

260^th place

1,423^rd place

1apnews.com

129^th place

89^th place

1handle.net

102^nd place

76^th place

1theglobeandmail.com

293^rd place

203^rd place

1ctvnews.ca

768^th place

482^nd place

1nikkei.com

211^th place

915^th place

1pharmafield.co.uk

low place

1ox.ac.uk

613^th place

456^th place

1pharmanewsintel.com

low place

1fiercepharma.com

low place

8,921^st place

1scientificamerican.com

896^th place

674^th place

1gatesnotes.com

low place

1bio.org

low place

1nationalpost.com

818^th place

524^th place

1archive-it.org

910^th place

593^rd place

1medpagetoday.com

9,274^th place

5,856^th place

1vaccines.gov

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1biopharma-reporter.com

low place

1thenationalnews.com

1,682^nd place

1,092^nd place

1clinicaltrialsarena.com

low place

1businesswire.com

615^th place

407^th place

1heidi.news

low place

1ghostarchive.org

32^nd place

21^st place

1modernatx.com

low place

admin.ch (Global: 279^th place; English: 551^st place)

bag.admin.ch

"Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 19 December 2020. Archived from the original on 10 January 2021. Retrieved 19 December 2020.
"COVID-19: Switzerland can start vaccinating vulnerable groups already in December" (Press release). Swiss Federal Office of Public Health. 19 December 2020. Archived from the original on 9 January 2021. Retrieved 19 December 2020.

apnews.com (Global: 129^th place; English: 89^th place)

MORITSUGU K (26 October 2022). "Afraid of needles? China using inhalable COVID-19 vaccine". AP NEWS. Retrieved 2 November 2022.

archive-it.org (Global: 910^th place; English: 593^rd place)

wayback.archive-it.org

Blackwell T (20 April 2020). "COVID-19 vaccine researchers say pandemic lockdown placing many serious obstacles to their work". National Post. Archived from the original on 24 April 2020. Retrieved 3 May 2020.

bbc.com (Global: 20^th place; English: 30^th place)

Roberts M (2 December 2020). "Covid Pfizer vaccine approved for use next week in UK". BBC News Online. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
Fox C, Kelion L (16 July 2020). "Russian spies 'target coronavirus vaccine'". BBC News. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
Coronavirus: North Korea and Russia hackers 'targeting vaccine' Archived 17 December 2021 at the Wayback Machine, (13 November 2020).
North Korea accused of hacking Pfizer for Covid-19 vaccine data Archived 24 April 2022 at the Wayback Machine, BBC News (16 February 2021).
"Covid-19 vaccine: Margaret Keenan 'so privileged' to get first jab". BBC News Online. 8 December 2020. Archived from the original on 8 December 2020. Retrieved 8 December 2020.
"Covid: Russia begins vaccinations in Moscow". BBC News Online. 5 December 2020. Archived from the original on 1 June 2022. Retrieved 18 January 2021.

bio.org (Global: low place; English: low place)

"Clinical Development Success Rates 2006–2015" (PDF). BIO Industry Analysis. June 2016. Archived (PDF) from the original on 12 September 2019. Retrieved 23 March 2020.

biopharma-reporter.com (Global: low place; English: low place)

Byrne J (19 October 2020). "Moderna COVID-19 vaccine under rolling review process in Canada, EU". BioPharma-Reporter.com, William Reed Business Media Ltd. Archived from the original on 25 February 2021. Retrieved 25 November 2020.

bloomberg.com (Global: 99^th place; English: 77^th place)

Sink J, Fabian J, Griffin R (15 May 2020). "Trump introduces 'Warp Speed' leaders to hasten COVID-19 vaccine". Bloomberg. Archived from the original on 21 May 2020. Retrieved 15 May 2020.
Griffith R, Jacobs J (3 June 2020). "White House Works With Seven Drugmakers in 'Warp Speed' Push". Bloomberg. Archived from the original on 3 June 2020. Retrieved 4 June 2020.

bna.bh (Global: low place; English: low place)

"Bahrain second in the world to approve the Pfizer/BioNTech Covid-19 vaccine". Bahrain News Agency. 4 December 2020. Archived from the original on 17 December 2020. Retrieved 9 December 2020.

businesswire.com (Global: 615^th place; English: 407^th place)

"Biopharma Leaders Unite to Stand with Science" (Press release). 8 September 2020. Archived from the original on 1 January 2021. Retrieved 31 December 2020 – via Business Wire.

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

"Government of Canada funds 49 additional COVID-19 research projects – Details of the funded projects". Government of Canada. 23 March 2020. Archived from the original on 22 March 2020. Retrieved 23 March 2020.
"Government of Canada's research response to COVID-19". Government of Canada. 23 April 2020. Archived from the original on 13 May 2020. Retrieved 4 May 2020.

cbc.ca (Global: 115^th place; English: 82^nd place)

"COVID-19 pandemic reveals the risks of relying on private sector for life-saving vaccines, says expert". CBC Radio. 8 May 2020. Archived from the original on 13 May 2020. Retrieved 8 June 2020.

cdc.gov (Global: 218^th place; English: 212^th place)

Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
"How flu vaccine effectiveness and efficacy are measured". Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, US Department of Health and Human Services. 29 January 2016. Archived from the original on 7 May 2020. Retrieved 6 May 2020.
"Principles of epidemiology, Section 8: Concepts of disease occurrence". Centers for Disease Control and Prevention, Center for Surveillance, Epidemiology, and Laboratory Services, US Department of Health and Human Services. 18 May 2012. Archived from the original on 6 April 2020. Retrieved 6 May 2020.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (December 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (50): 1922–24. doi:10.15585/mmwr.mm6950e2. PMC 7745957. PMID 33332292. Archived (PDF) from the original on 19 December 2020. Retrieved 18 January 2021.

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

AstraZeneca (12 April 2021). "A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19". Iqvia Pty Ltd. Archived from the original on 23 August 2020. Retrieved 11 June 2021.

clinicaltrialsarena.com (Global: low place; English: low place)

Healthcare G (2 July 2020). "FDA may be risk-averse to grant emergency use for a Covid-19 vaccine; political pressure and hazy EUA standards are factors". Clinical Trials Arena. ClinicalTrials Arena, Verdict Media, Ltd. Archived from the original on 22 July 2020. Retrieved 22 August 2020.

cnbc.com (Global: 220^th place; English: 155^th place)

Lovelace Jr B (19 December 2020). "FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution". CNBC. Archived from the original on 26 January 2021. Retrieved 19 December 2020.

cnn.com (Global: 28^th place; English: 26^th place)

cnn.com

Kuznia R, Polglase K, Mezzofiore G (1 May 2020). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN. Archived from the original on 13 May 2020. Retrieved 2 May 2020.
Howard J, Stracqualursi V (18 June 2020). "Fauci warns of 'anti-science bias' being a problem in US". CNN. Archived from the original on 21 June 2020. Retrieved 21 June 2020.

edition.cnn.com

"Fact-checking the battle for credit over Pfizer's vaccine announcement". CNN. 10 November 2020. Archived from the original on 16 November 2020. Retrieved 13 November 2020. Pfizer is one of various vaccine manufacturers participating in Operation Warp Speed as a supplier of a potential COVID-19 vaccine," Castillo said in an email. "While Pfizer did reach an advanced purchase agreement with the U.S. government, the company did not accept (Biomedical Advanced Research and Development Authority) funding for the research and development process. All the investment for R&D was made by Pfizer at risk. Dr. Jansen was emphasizing that last point.

ctvnews.ca (Global: 768^th place; English: 482^nd place)

Aiello R (4 May 2020). "'A global challenge': PM Trudeau commits $850 million to global fight against COVID-19". CTV News. Archived from the original on 10 May 2020. Retrieved 4 May 2020.

doi.org (Global: 2^nd place; English: 2^nd place)

Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–306. Bibcode:2020NRvDD..19..305T. doi:10.1038/d41573-020-00073-5. PMID 32273591.
Gates B (February 2020). "Responding to Covid-19: A once-in-a-century pandemic?". The New England Journal of Medicine. 382 (18): 1677–79. doi:10.1056/nejmp2003762. PMID 32109012.
Fauci AS, Lane HC, Redfield RR (March 2020). "Covid-19: Navigating the uncharted". The New England Journal of Medicine. 382 (13): 1268–69. doi:10.1056/nejme2002387. PMC 7121221. PMID 32109011.
Le TT, Cramer JP, Chen R, Mayhew S (October 2020). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (10): 667–668. doi:10.1038/d41573-020-00151-8. PMID 32887942. S2CID 221503034.
Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK (May 2020). "Ensuring global access to COVID‑19 vaccines". Lancet. 395 (10234): 1405–06. doi:10.1016/S0140-6736(20)30763-7. PMC 7271264. PMID 32243778. CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes Phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
Ye Y, Zhang Q, Wei X, Cao Z, Yuan HY, Zeng DD (February 2022). "Equitable access to COVID-19 vaccines makes a life-saving difference to all countries". Nature Human Behaviour. 6 (2): 207–216. doi:10.1038/s41562-022-01289-8. PMC 8873023. PMID 35102361.
Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen JA (December 2018). "Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study". Lancet Global Health. 6 (12): e1386–96. doi:10.1016/S2214-109X(18)30346-2. PMC 7164811. PMID 30342925.
DiMasi JA, Grabowski HG, Hansen RW (May 2016). "Innovation in the pharmaceutical industry: New estimates of R&D costs". Journal of Health Economics. 47: 20–33. doi:10.1016/j.jhealeco.2016.01.012. hdl:10161/12742. PMID 26928437.
Moon S, Armstrong J, Hutler B, Upshur R, Katz R, Atuire C, Bhan A, Emanuel E, Faden R, Ghimire P, Greco D (29 January 2022). "Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability". The Lancet. 399 (10323): 487–494. doi:10.1016/S0140-6736(21)02344-8. ISSN 0140-6736. PMC 8797025. PMID 34902308.
Cohen J (15 May 2020). "U.S. 'Warp Speed' vaccine effort comes out of the shadows". Science. 368 (6492): 692–93. Bibcode:2020Sci...368..692C. doi:10.1126/science.368.6492.692. ISSN 0036-8075. PMID 32409451.
Cohen J (4 June 2020). "Top U.S. scientists left out of White House selection of COVID-19 vaccine short list". Science. doi:10.1126/science.abd1719. ISSN 0036-8075.
Pandamooz S, Jurek B, Meinung CP, Baharvand Z, Sahebi Shahem-abadi A, Haerteis S, Miyan JA, Downing J, Dianatpour M, Borhani-Haghighi A, Salehi MS (6 January 2022). "Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments". Annual Review of Pharmacology and Toxicology. 62 (1): 25–53. doi:10.1146/annurev-pharmtox-121120-012309. ISSN 0362-1642. PMID 33606962. S2CID 231970935.
Diamond MS, Pierson TC (May 2020). "The Challenges of Vaccine Development against a New Virus during a Pandemic". Cell Host & Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.
Thorp HH (March 2020). "Underpromise, overdeliver". Science. 367 (6485): 1405. Bibcode:2020Sci...367.1405T. doi:10.1126/science.abb8492. PMID 32205459.
Iwasaki A, Yang Y (June 2020). "The potential danger of suboptimal antibody responses in COVID-19". Nature Reviews. Immunology. 20 (6): 339–341. doi:10.1038/s41577-020-0321-6. PMC 7187142. PMID 32317716.
Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, Dekker CL, Didierlaurent AM, Graham BS, Martin SD, Molrine DC, Perlman S, Picard-Fraser PA, Pollard AJ, Qin C, Subbarao K, Cramer JP (June 2020). "Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines". Vaccine. 38 (31): 4783–4791. doi:10.1016/j.vaccine.2020.05.064. PMC 7247514. PMID 32507409.
Haynes BF, Corey L, Fernandes P, Gilbert PB, Hotez PJ, Rao S, Santos MR, Schuitemaker H, Watson M, Arvin A (4 November 2020). "Prospects for a safe COVID-19 vaccine". Science Translational Medicine. 12 (568) eabe0948. doi:10.1126/scitranslmed.abe0948. ISSN 1946-6242. PMID 33077678. S2CID 224809822.
Cohen J (June 2020). "Pandemic vaccines are about to face the real test". Science. 368 (6497): 1295–1296. Bibcode:2020Sci...368.1295C. doi:10.1126/science.368.6497.1295. PMID 32554572.
Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J (August 2013). "Vaccine hesitancy: an overview". Human Vaccines & Immunotherapeutics. 9 (8): 1763–73. doi:10.4161/hv.24657. PMC 3906279. PMID 23584253.
Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JM, Weir CJ, Wheeler GM, Yap C, Jaki T (February 2018). "Adaptive designs in clinical trials: why use them, and how to run and report them". BMC Medicine. 16 (1) 29. doi:10.1186/s12916-018-1017-7. PMC 5830330. PMID 29490655.
Lambkin-Williams R, Noulin N, Mann A, Catchpole A, Gilbert AS (June 2018). "The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics". Respiratory Research. 19 (1) 123. doi:10.1186/s12931-018-0784-1. PMC 6013893. PMID 29929556.
Eyal N, Lipsitch M, Smith PG (May 2020). "Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure". The Journal of Infectious Diseases. 221 (11): 1752–1756. doi:10.1093/infdis/jiaa152. PMC 7184325. PMID 32232474.
Callaway E (April 2020). "Should scientists infect healthy people with the coronavirus to test vaccines?". Nature. 580 (7801): 17. Bibcode:2020Natur.580...17C. doi:10.1038/d41586-020-00927-3. PMID 32218549.
Cohen J (31 March 2020). "Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn". Science. doi:10.1126/science.abc0006.
Callaway E (October 2020). "Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials". Nature. 586 (7831): 651–652. Bibcode:2020Natur.586..651C. doi:10.1038/d41586-020-02821-4. PMID 33082550. S2CID 224823112.
Malik AA, McFadden SM, Elharake J, Omer SB (September 2020). "Determinants of COVID-19 vaccine acceptance in the US". eClinicalMedicine. 26 100495. doi:10.1016/j.eclinm.2020.100495. PMC 7423333. PMID 32838242.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (December 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (50): 1922–24. doi:10.15585/mmwr.mm6950e2. PMC 7745957. PMID 33332292. Archived (PDF) from the original on 19 December 2020. Retrieved 18 January 2021.
Cavaleri M, Enzmann H, Straus S, Cooke E (January 2021). "The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines". Lancet. 397 (10272): 355–357. doi:10.1016/s0140-6736(21)00085-4. ISSN 0140-6736. PMC 7833511. PMID 33453149.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Vaccines: The Emergency Authorisation Procedure". European Medicines Agency. 2020. Archived from the original on 24 September 2020. Retrieved 21 August 2020.
"EMA starts first rolling review of a COVID-19 vaccine in the EU" (Press release). European Medicines Agency (EMA). 1 October 2020. Archived from the original on 1 October 2020. Retrieved 1 October 2020.
"COVID-19 vaccines: key facts". European Medicines Agency (EMA). 14 September 2020. Archived from the original on 7 October 2020. Retrieved 1 October 2020.
"EMA starts second rolling review of a COVID-19 vaccine" (Press release). European Medicines Agency (EMA). 5 October 2020. Archived from the original on 6 October 2020. Retrieved 6 October 2020.
"Update on rolling review of AstraZeneca's COVID-19 vaccine" (Press release). European Medicines Agency (EMA). 30 December 2020. Archived from the original on 30 December 2020. Retrieved 30 December 2020.
"EMA publishes safety monitoring plan and guidance on risk management planning for COVID-19 vaccines" (Press release). European Medicines Agency (EMA). 13 November 2020. Archived from the original on 13 November 2020. Retrieved 13 November 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"EMA considerations on COVID-19 vaccine approval". European Medicines Agency (EMA). 19 November 2020. Archived from the original on 19 November 2020. Retrieved 19 November 2020.
"EMA starts rolling review of mRNA COVID-19 vaccine by Moderna Biotech Spain, S.L." (Press release). European Medicines Agency (EMA). 16 November 2020. Archived from the original on 16 November 2020. Retrieved 16 November 2020.
"EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine" (Press release). European Medicines Agency (EMA). 1 December 2020. Archived from the original on 1 December 2020. Retrieved 1 December 2020.
"EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2" (Press release). European Medicines Agency (EMA). 1 December 2020. Archived from the original on 1 December 2020. Retrieved 1 December 2020.
"Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application" (Press release). European Medicines Agency (EMA). 15 December 2020. Archived from the original on 15 December 2020. Retrieved 15 December 2020.
"Update on assessment of marketing authorisation application for Moderna's mRNA-1273 COVID-19 vaccine" (Press release). European Medicines Agency (EMA). 17 December 2020. Archived from the original on 17 December 2020. Retrieved 17 December 2020.
"EMA starts rolling review of Janssen's COVID-19 vaccine Ad26.COV2.S" (Press release). European Medicines Agency (EMA). 1 December 2020. Archived from the original on 8 January 2021. Retrieved 1 December 2020.
"EMA recommends first COVID-19 vaccine for authorisation in the EU" (Press release). European Medicines Agency (EMA). 21 December 2020. Archived from the original on 30 January 2021. Retrieved 21 December 2020.
"Comirnaty EPAR". European Medicines Agency (EMA). 21 December 2020. Archived from the original on 24 January 2022. Retrieved 23 December 2020.
"COVID-19 Vaccine Moderna EPAR". European Medicines Agency (EMA). 4 January 2021. Archived from the original on 12 March 2021. Retrieved 20 January 2021.
"EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU" (Press release). European Medicines Agency. 6 January 2021. Archived from the original on 17 March 2021. Retrieved 6 January 2021.
"EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca". European Medicines Agency (EMA). 12 January 2021. Archived from the original on 30 March 2021. Retrieved 12 January 2021.
"COVID-19 Vaccine AstraZeneca". European Medicines Agency (EMA). 28 January 2021. Archived from the original on 16 February 2021. Retrieved 29 January 2021.
"EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU" (Press release). European Medicines Agency (EMA). 29 January 2021. Archived from the original on 9 February 2021. Retrieved 29 January 2021.
"EMA starts rolling review of Novavax's COVID-19 vaccine (NVX-CoV2373)". European Medicines Agency (EMA). 3 February 2021. Archived from the original on 2 July 2021. Retrieved 3 February 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"EMA starts rolling review of CureVac's COVID-19 vaccine (CVnCoV)" (Press release). European Medicines Agency (EMA). 11 February 2021. Archived from the original on 12 February 2021. Retrieved 12 February 2021.
"EMA preparing guidance to tackle COVID-19 variants" (Press release). European Medicines Agency (EMA). 10 February 2021. Archived from the original on 15 February 2021. Retrieved 10 February 2021.
"EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen". European Medicines Agency (EMA). 16 February 2021. Archived from the original on 16 February 2021. Retrieved 16 February 2021.
"COVID-19 Vaccine Janssen EPAR". European Medicines Agency (EMA). 5 March 2021. Archived from the original on 15 March 2021. Retrieved 11 July 2021.
"EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU". European Medicines Agency (EMA) (Press release). 11 March 2021. Archived from the original on 11 March 2021. Retrieved 11 July 2021.
"EMA starts rolling review of the Sputnik V COVID-19 vaccine" (Press release). European Medicines Agency (EMA). 4 March 2021. Archived from the original on 4 March 2021. Retrieved 4 March 2021.
"EMA starts evaluating use of COVID-19 vaccine Comirnaty in young people aged 12 to 15". European Medicines Agency (EMA) (Press release). 3 May 2021. Archived from the original on 7 May 2021. Retrieved 7 May 2021.
"EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated". European Medicines Agency (EMA) (Press release). 4 May 2021. Archived from the original on 4 May 2021. Retrieved 7 May 2021.

ec.europa.eu

"Questions and Answers: COVID-19 vaccination in the EU". European Commission. 21 December 2020. Archived from the original on 29 January 2021. Retrieved 21 December 2020.
"Statement by President von der Leyen on the marketing authorisation of the BioNTech-Pfizer vaccine against COVID-19". European Commission. Archived from the original on 11 January 2021. Retrieved 21 December 2020.
"Comirnaty". Union Register of medicinal products. Archived from the original on 24 January 2021. Retrieved 29 January 2021.
"European Commission authorises second safe and effective vaccine against COVID-19". European Commission (Press release). Archived from the original on 20 January 2021. Retrieved 6 January 2021.
"COVID-19 Vaccine Moderna". Union Register of medicinal products. Archived from the original on 24 January 2021. Retrieved 14 January 2021.
"European Commission authorises third safe and effective vaccine against COVID-19". European Commission (Press release). Archived from the original on 10 February 2021. Retrieved 29 January 2021.
"COVID-19 Vaccine AstraZeneca". Union Register of medicinal products. Archived from the original on 26 March 2021. Retrieved 29 January 2021.
"European Commission authorises fourth safe and effective vaccine against COVID-19". European Commission (Press release). Archived from the original on 25 August 2020. Retrieved 11 July 2021.

fda.gov (Global: 447^th place; English: 338^th place)

"FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 17 March 2021. Retrieved 18 December 2020.
"The drug development process". U.S. Food and Drug Administration (FDA). 4 January 2018. Archived from the original on 22 February 2020. Retrieved 12 April 2020.
"Adaptive designs for clinical trials of drugs and biologics: Guidance for industry" (PDF). U.S. Food and Drug Administration (FDA). 1 November 2019. Archived from the original on 13 December 2019. Retrieved 3 April 2020.
"Emergency Use Authorization for Vaccines Explained". U.S. Food and Drug Administration (FDA). 20 November 2020. Archived from the original on 20 November 2020. Retrieved 20 November 2020. This article incorporates text from this source, which is in the public domain.

fiercepharma.com (Global: low place; English: 8,921^st place)

Blankenship K (4 June 2020). "AstraZeneca unveils massive $750M deal in effort to produce billions of COVID-19 shots". FiercePharma. Archived from the original on 10 June 2020. Retrieved 8 June 2020.

gatesnotes.com (Global: low place; English: low place)

Gates B (30 April 2020). "The vaccine race explained: What you need to know about the COVID-19 vaccine". The Gates Notes. Archived from the original on 14 May 2020. Retrieved 2 May 2020.

ghostarchive.org (Global: 32^nd place; English: 21^st place)

Bird S (14 November 2020). "Trademark filings offer tantalising glimpse of coronavirus vaccine's name". The Daily Telegraph. Archived from the original on 12 January 2022. Retrieved 19 December 2020.

globalnews.ca (Global: 985^th place; English: 583^rd place)

Abedi M (23 March 2020). "Canada to spend $192M on developing COVID-19 vaccine". Global News. Archived from the original on 9 April 2020. Retrieved 24 March 2020.
Dangerfield K (20 November 2020). "Pfizer files for emergency use of coronavirus vaccine in U.S. – what about in Canada?". Global News. Archived from the original on 25 January 2021. Retrieved 25 November 2020.

gov.uk (Global: 432^nd place; English: 278^th place)

"Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine". Medicines & Healthcare products Regulatory Agency (MHRA). 8 December 2020. Archived from the original on 15 March 2021. Retrieved 13 December 2020.
"Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 3 December 2020. Archived from the original on 26 February 2021. Retrieved 19 December 2020.
"UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020. Archived from the original on 17 March 2021. Retrieved 2 December 2020.
"Oxford University/AstraZeneca vaccine authorised by UK medicines regulator". Gov.uk. Department of Health and Social Care. 30 December 2020. Archived from the original on 16 March 2021. Retrieved 30 December 2020.
"Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Archived from the original on 9 March 2021. Retrieved 4 January 2021.
"Conditions of Authorisation for COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Archived from the original on 18 February 2021. Retrieved 4 January 2021.

gulfnews.com (Global: 765^th place; English: 523^rd place)

"UAE: Ministry of Health announces 86 per cent vaccine efficacy". Gulf News. Archived from the original on 24 December 2020. Retrieved 9 December 2020.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

DiMasi JA, Grabowski HG, Hansen RW (May 2016). "Innovation in the pharmaceutical industry: New estimates of R&D costs". Journal of Health Economics. 47: 20–33. doi:10.1016/j.jhealeco.2016.01.012. hdl:10161/12742. PMID 26928437.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–306. Bibcode:2020NRvDD..19..305T. doi:10.1038/d41573-020-00073-5. PMID 32273591.
Cohen J (15 May 2020). "U.S. 'Warp Speed' vaccine effort comes out of the shadows". Science. 368 (6492): 692–93. Bibcode:2020Sci...368..692C. doi:10.1126/science.368.6492.692. ISSN 0036-8075. PMID 32409451.
Thorp HH (March 2020). "Underpromise, overdeliver". Science. 367 (6485): 1405. Bibcode:2020Sci...367.1405T. doi:10.1126/science.abb8492. PMID 32205459.
Cohen J (June 2020). "Pandemic vaccines are about to face the real test". Science. 368 (6497): 1295–1296. Bibcode:2020Sci...368.1295C. doi:10.1126/science.368.6497.1295. PMID 32554572.
Callaway E (April 2020). "Should scientists infect healthy people with the coronavirus to test vaccines?". Nature. 580 (7801): 17. Bibcode:2020Natur.580...17C. doi:10.1038/d41586-020-00927-3. PMID 32218549.
Callaway E (October 2020). "Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials". Nature. 586 (7831): 651–652. Bibcode:2020Natur.586..651C. doi:10.1038/d41586-020-02821-4. PMID 33082550. S2CID 224823112.

hbr.org (Global: 2,754^th place; English: 1,686^th place)

Weintraub R, Yadav P, Berkley S (2 April 2020). "A COVID-19 vaccine will need equitable, global distribution". Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.

heidi.news (Global: low place; English: low place)

Pralong J (23 December 2020). "La piqûre de l'espoir pratiquée à Lucerne". Heidi.news. Archived from the original on 10 January 2021. Retrieved 23 December 2020.

medpagetoday.com (Global: 9,274^th place; English: 5,856^th place)

Hackethal V (16 March 2021). "Why ADE Hasn't Been a Problem With COVID Vaccines". www.medpagetoday.com. Archived from the original on 25 June 2021. Retrieved 1 July 2021.

modernatx.com (Global: low place; English: low place)

investors.modernatx.com

"Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization". Moderna, Inc. (Press release). 30 November 2020. Archived from the original on 30 November 2020. Retrieved 30 November 2020.

nationalpost.com (Global: 818^th place; English: 524^th place)

Blackwell T (20 April 2020). "COVID-19 vaccine researchers say pandemic lockdown placing many serious obstacles to their work". National Post. Archived from the original on 24 April 2020. Retrieved 3 May 2020.

nbcnews.com (Global: 137^th place; English: 101^st place)

Talmazan Y, Simmons K, Saravia L (18 May 2020). "China's Xi announces $2B for coronavirus response as WHO faces calls for investigation". NBC News. Archived from the original on 18 May 2020. Retrieved 18 May 2020.
Lee CE, Welker K, Perlmutter-Gumbiner E (1 May 2020). "Health officials eyeing at least one of 14 potential coronavirus vaccines to fast-track". NBC News. Archived from the original on 11 May 2020. Retrieved 2 May 2020.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–306. Bibcode:2020NRvDD..19..305T. doi:10.1038/d41573-020-00073-5. PMID 32273591.
Gates B (February 2020). "Responding to Covid-19: A once-in-a-century pandemic?". The New England Journal of Medicine. 382 (18): 1677–79. doi:10.1056/nejmp2003762. PMID 32109012.
Fauci AS, Lane HC, Redfield RR (March 2020). "Covid-19: Navigating the uncharted". The New England Journal of Medicine. 382 (13): 1268–69. doi:10.1056/nejme2002387. PMC 7121221. PMID 32109011.
Le TT, Cramer JP, Chen R, Mayhew S (October 2020). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (10): 667–668. doi:10.1038/d41573-020-00151-8. PMID 32887942. S2CID 221503034.
Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK (May 2020). "Ensuring global access to COVID‑19 vaccines". Lancet. 395 (10234): 1405–06. doi:10.1016/S0140-6736(20)30763-7. PMC 7271264. PMID 32243778. CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes Phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
Ye Y, Zhang Q, Wei X, Cao Z, Yuan HY, Zeng DD (February 2022). "Equitable access to COVID-19 vaccines makes a life-saving difference to all countries". Nature Human Behaviour. 6 (2): 207–216. doi:10.1038/s41562-022-01289-8. PMC 8873023. PMID 35102361.
Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen JA (December 2018). "Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study". Lancet Global Health. 6 (12): e1386–96. doi:10.1016/S2214-109X(18)30346-2. PMC 7164811. PMID 30342925.
DiMasi JA, Grabowski HG, Hansen RW (May 2016). "Innovation in the pharmaceutical industry: New estimates of R&D costs". Journal of Health Economics. 47: 20–33. doi:10.1016/j.jhealeco.2016.01.012. hdl:10161/12742. PMID 26928437.
Moon S, Armstrong J, Hutler B, Upshur R, Katz R, Atuire C, Bhan A, Emanuel E, Faden R, Ghimire P, Greco D (29 January 2022). "Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability". The Lancet. 399 (10323): 487–494. doi:10.1016/S0140-6736(21)02344-8. ISSN 0140-6736. PMC 8797025. PMID 34902308.
Cohen J (15 May 2020). "U.S. 'Warp Speed' vaccine effort comes out of the shadows". Science. 368 (6492): 692–93. Bibcode:2020Sci...368..692C. doi:10.1126/science.368.6492.692. ISSN 0036-8075. PMID 32409451.
Pandamooz S, Jurek B, Meinung CP, Baharvand Z, Sahebi Shahem-abadi A, Haerteis S, Miyan JA, Downing J, Dianatpour M, Borhani-Haghighi A, Salehi MS (6 January 2022). "Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments". Annual Review of Pharmacology and Toxicology. 62 (1): 25–53. doi:10.1146/annurev-pharmtox-121120-012309. ISSN 0362-1642. PMID 33606962. S2CID 231970935.
Diamond MS, Pierson TC (May 2020). "The Challenges of Vaccine Development against a New Virus during a Pandemic". Cell Host & Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.
Thorp HH (March 2020). "Underpromise, overdeliver". Science. 367 (6485): 1405. Bibcode:2020Sci...367.1405T. doi:10.1126/science.abb8492. PMID 32205459.
Iwasaki A, Yang Y (June 2020). "The potential danger of suboptimal antibody responses in COVID-19". Nature Reviews. Immunology. 20 (6): 339–341. doi:10.1038/s41577-020-0321-6. PMC 7187142. PMID 32317716.
Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, Dekker CL, Didierlaurent AM, Graham BS, Martin SD, Molrine DC, Perlman S, Picard-Fraser PA, Pollard AJ, Qin C, Subbarao K, Cramer JP (June 2020). "Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines". Vaccine. 38 (31): 4783–4791. doi:10.1016/j.vaccine.2020.05.064. PMC 7247514. PMID 32507409.
Haynes BF, Corey L, Fernandes P, Gilbert PB, Hotez PJ, Rao S, Santos MR, Schuitemaker H, Watson M, Arvin A (4 November 2020). "Prospects for a safe COVID-19 vaccine". Science Translational Medicine. 12 (568) eabe0948. doi:10.1126/scitranslmed.abe0948. ISSN 1946-6242. PMID 33077678. S2CID 224809822.
Cohen J (June 2020). "Pandemic vaccines are about to face the real test". Science. 368 (6497): 1295–1296. Bibcode:2020Sci...368.1295C. doi:10.1126/science.368.6497.1295. PMID 32554572.
Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J (August 2013). "Vaccine hesitancy: an overview". Human Vaccines & Immunotherapeutics. 9 (8): 1763–73. doi:10.4161/hv.24657. PMC 3906279. PMID 23584253.
Winter SS, Page-Reeves JM, Page KA, Haozous E, Solares A, Nicole Cordova C, Larson RS (May 2018). "Inclusion of special populations in clinical research: important considerations and guidelines". Journal of Clinical and Translational Research (Review). 4 (1): 56–69. PMC 6410628. PMID 30873495.
Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JM, Weir CJ, Wheeler GM, Yap C, Jaki T (February 2018). "Adaptive designs in clinical trials: why use them, and how to run and report them". BMC Medicine. 16 (1) 29. doi:10.1186/s12916-018-1017-7. PMC 5830330. PMID 29490655.
Lambkin-Williams R, Noulin N, Mann A, Catchpole A, Gilbert AS (June 2018). "The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics". Respiratory Research. 19 (1) 123. doi:10.1186/s12931-018-0784-1. PMC 6013893. PMID 29929556.
Eyal N, Lipsitch M, Smith PG (May 2020). "Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure". The Journal of Infectious Diseases. 221 (11): 1752–1756. doi:10.1093/infdis/jiaa152. PMC 7184325. PMID 32232474.
Callaway E (April 2020). "Should scientists infect healthy people with the coronavirus to test vaccines?". Nature. 580 (7801): 17. Bibcode:2020Natur.580...17C. doi:10.1038/d41586-020-00927-3. PMID 32218549.
Callaway E (October 2020). "Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials". Nature. 586 (7831): 651–652. Bibcode:2020Natur.586..651C. doi:10.1038/d41586-020-02821-4. PMID 33082550. S2CID 224823112.
Malik AA, McFadden SM, Elharake J, Omer SB (September 2020). "Determinants of COVID-19 vaccine acceptance in the US". eClinicalMedicine. 26 100495. doi:10.1016/j.eclinm.2020.100495. PMC 7423333. PMID 32838242.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (December 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (50): 1922–24. doi:10.15585/mmwr.mm6950e2. PMC 7745957. PMID 33332292. Archived (PDF) from the original on 19 December 2020. Retrieved 18 January 2021.
Cavaleri M, Enzmann H, Straus S, Cooke E (January 2021). "The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines". Lancet. 397 (10272): 355–357. doi:10.1016/s0140-6736(21)00085-4. ISSN 0140-6736. PMC 7833511. PMID 33453149.

ncbi.nlm.nih.gov

Fauci AS, Lane HC, Redfield RR (March 2020). "Covid-19: Navigating the uncharted". The New England Journal of Medicine. 382 (13): 1268–69. doi:10.1056/nejme2002387. PMC 7121221. PMID 32109011.
Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK (May 2020). "Ensuring global access to COVID‑19 vaccines". Lancet. 395 (10234): 1405–06. doi:10.1016/S0140-6736(20)30763-7. PMC 7271264. PMID 32243778. CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes Phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
Ye Y, Zhang Q, Wei X, Cao Z, Yuan HY, Zeng DD (February 2022). "Equitable access to COVID-19 vaccines makes a life-saving difference to all countries". Nature Human Behaviour. 6 (2): 207–216. doi:10.1038/s41562-022-01289-8. PMC 8873023. PMID 35102361.
Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen JA (December 2018). "Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study". Lancet Global Health. 6 (12): e1386–96. doi:10.1016/S2214-109X(18)30346-2. PMC 7164811. PMID 30342925.
Moon S, Armstrong J, Hutler B, Upshur R, Katz R, Atuire C, Bhan A, Emanuel E, Faden R, Ghimire P, Greco D (29 January 2022). "Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability". The Lancet. 399 (10323): 487–494. doi:10.1016/S0140-6736(21)02344-8. ISSN 0140-6736. PMC 8797025. PMID 34902308.
Diamond MS, Pierson TC (May 2020). "The Challenges of Vaccine Development against a New Virus during a Pandemic". Cell Host & Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.
Iwasaki A, Yang Y (June 2020). "The potential danger of suboptimal antibody responses in COVID-19". Nature Reviews. Immunology. 20 (6): 339–341. doi:10.1038/s41577-020-0321-6. PMC 7187142. PMID 32317716.
Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, Dekker CL, Didierlaurent AM, Graham BS, Martin SD, Molrine DC, Perlman S, Picard-Fraser PA, Pollard AJ, Qin C, Subbarao K, Cramer JP (June 2020). "Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines". Vaccine. 38 (31): 4783–4791. doi:10.1016/j.vaccine.2020.05.064. PMC 7247514. PMID 32507409.
Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J (August 2013). "Vaccine hesitancy: an overview". Human Vaccines & Immunotherapeutics. 9 (8): 1763–73. doi:10.4161/hv.24657. PMC 3906279. PMID 23584253.
Winter SS, Page-Reeves JM, Page KA, Haozous E, Solares A, Nicole Cordova C, Larson RS (May 2018). "Inclusion of special populations in clinical research: important considerations and guidelines". Journal of Clinical and Translational Research (Review). 4 (1): 56–69. PMC 6410628. PMID 30873495.
Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JM, Weir CJ, Wheeler GM, Yap C, Jaki T (February 2018). "Adaptive designs in clinical trials: why use them, and how to run and report them". BMC Medicine. 16 (1) 29. doi:10.1186/s12916-018-1017-7. PMC 5830330. PMID 29490655.
Lambkin-Williams R, Noulin N, Mann A, Catchpole A, Gilbert AS (June 2018). "The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics". Respiratory Research. 19 (1) 123. doi:10.1186/s12931-018-0784-1. PMC 6013893. PMID 29929556.
Eyal N, Lipsitch M, Smith PG (May 2020). "Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure". The Journal of Infectious Diseases. 221 (11): 1752–1756. doi:10.1093/infdis/jiaa152. PMC 7184325. PMID 32232474.
Malik AA, McFadden SM, Elharake J, Omer SB (September 2020). "Determinants of COVID-19 vaccine acceptance in the US". eClinicalMedicine. 26 100495. doi:10.1016/j.eclinm.2020.100495. PMC 7423333. PMID 32838242.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (December 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (50): 1922–24. doi:10.15585/mmwr.mm6950e2. PMC 7745957. PMID 33332292. Archived (PDF) from the original on 19 December 2020. Retrieved 18 January 2021.
Cavaleri M, Enzmann H, Straus S, Cooke E (January 2021). "The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines". Lancet. 397 (10272): 355–357. doi:10.1016/s0140-6736(21)00085-4. ISSN 0140-6736. PMC 7833511. PMID 33453149.

nikkei.com (Global: 211^th place; English: 915^th place)

asia.nikkei.com

Takada N, Satake M (2 May 2020). "US and China unleash wallets in race for coronavirus vaccine". Nikkei Asian Review. Archived from the original on 10 May 2020. Retrieved 3 May 2020.

nytimes.com (Global: 7^th place; English: 7^th place)

Kramer AE (19 September 2020). "Russia Is Slow to Administer Virus Vaccine Despite Kremlin's Approval". The New York Times. ISSN 0362-4331. Archived from the original on 27 September 2020. Retrieved 28 September 2020.
Mueller B (2 December 2020). "U.K. Approves Pfizer Coronavirus Vaccine, a First in the West". The New York Times. Archived from the original on 28 January 2021. Retrieved 2 December 2020.
Thomas K, LaFraniere S, Weiland N, Goodnough A, Haberman M (12 December 2020). "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away". The New York Times. Archived from the original on 12 December 2020. Retrieved 12 December 2020.
Corum J, Zimmer C (17 December 2020). "How the Oxford-AstraZeneca Vaccine Works". The New York Times. Archived from the original on 5 January 2022. Retrieved 2 May 2021.
Sanger DE, Kirkpatrick DD, Zimmer C, Thomas K, Wee SL (2 May 2020). "With Pressure Growing, Global Race for a Vaccine Intensifies". The New York Times. ISSN 0362-4331. Archived from the original on 11 May 2020. Retrieved 2 May 2020.
Hoffman J (18 July 2020). "Mistrust of a coronavirus vaccine could imperil widespread immunity". The New York Times. Archived from the original on 27 September 2020. Retrieved 23 August 2020.
Mueller B (8 December 2020). "As U.K. Begins Vaccinations, a Glimpse of Life After Covid". The New York Times. Archived from the original on 14 December 2020. Retrieved 20 December 2020.
"Moderna Applies for Emergency F.D.A. Approval for Its Coronavirus Vaccine". The New York Times. 30 November 2020. Archived from the original on 30 November 2020. Retrieved 30 November 2020.

ox.ac.uk (Global: 613^th place; English: 456^th place)

"Landmark partnership announced for development of COVID-19 vaccine". University of Oxford. 30 April 2020. Archived from the original on 13 May 2020. Retrieved 3 May 2020.

pfizer.com (Global: low place; English: low place)

"Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine". Pfizer (Press release). 20 November 2020. Archived from the original on 29 January 2021. Retrieved 20 November 2020.

pharmafield.co.uk (Global: low place; English: low place)

Morriss E (22 April 2020). "Government launches coronavirus vaccine taskforce as human clinical trials start". Pharmafield. Archived from the original on 26 June 2020. Retrieved 3 May 2020.

pharmanewsintel.com (Global: low place; English: low place)

McGrail S (15 April 2020). "Sanofi, GSK partner to develop adjuvanted COVID-19 vaccine". PharmaNewsIntelligence. Archived from the original on 9 May 2020. Retrieved 4 May 2020.

reuters.com (Global: 49^th place; English: 47^th place)

Tétrault-Farber M, Vasilyeva G (31 March 2021). "Russia registers world's first COVID-19 vaccine for animals". Reuters. Archived from the original on 17 December 2021. Retrieved 4 April 2021.
Steenhuysen J, Eisler P, Martell A, Nebehay S (27 April 2020). "Special Report: Countries, companies risk billions in race for coronavirus vaccine". Reuters. Archived from the original on 15 May 2020. Retrieved 2 May 2020.
Ore D (23 July 2020). "Mexico says China plans $1 billion loan to ease Latam access to virus vaccine". Reuters. Archived from the original on 25 September 2020. Retrieved 16 August 2020.
Barrington L (3 November 2020). "Bahrain latest country to vaccinate frontline workers with COVID-19 shot". Reuters. Archived from the original on 30 December 2021. Retrieved 18 November 2020.

scientificamerican.com (Global: 896^th place; English: 674^th place)

Schmidt C (1 June 2020). "Genetic Engineering Could Make a COVID-19 Vaccine in Months Rather Than Years". Scientific American. Archived from the original on 11 October 2020. Retrieved 26 August 2020.

scmp.com (Global: 362^nd place; English: 245^th place)

"WHO 'backed China's emergency use' of experimental Covid-19 vaccines". South China Morning Post. 25 September 2020. Archived from the original on 26 September 2020. Retrieved 26 September 2020.
"China promises Mekong neighbours access to Chinese Covid-19 vaccine". South China Morning Post. 24 August 2020. Archived from the original on 25 September 2020. Retrieved 24 August 2020.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Le TT, Cramer JP, Chen R, Mayhew S (October 2020). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (10): 667–668. doi:10.1038/d41573-020-00151-8. PMID 32887942. S2CID 221503034.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
Pandamooz S, Jurek B, Meinung CP, Baharvand Z, Sahebi Shahem-abadi A, Haerteis S, Miyan JA, Downing J, Dianatpour M, Borhani-Haghighi A, Salehi MS (6 January 2022). "Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments". Annual Review of Pharmacology and Toxicology. 62 (1): 25–53. doi:10.1146/annurev-pharmtox-121120-012309. ISSN 0362-1642. PMID 33606962. S2CID 231970935.
Haynes BF, Corey L, Fernandes P, Gilbert PB, Hotez PJ, Rao S, Santos MR, Schuitemaker H, Watson M, Arvin A (4 November 2020). "Prospects for a safe COVID-19 vaccine". Science Translational Medicine. 12 (568) eabe0948. doi:10.1126/scitranslmed.abe0948. ISSN 1946-6242. PMID 33077678. S2CID 224809822.
Callaway E (October 2020). "Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials". Nature. 586 (7831): 651–652. Bibcode:2020Natur.586..651C. doi:10.1038/d41586-020-02821-4. PMID 33082550. S2CID 224823112.

statnews.com (Global: 8,771^st place; English: 5,253^rd place)

Ahmed DD (4 June 2020). "Oxford, AstraZeneca COVID-19 deal reinforces 'vaccine sovereignty'". Stat. Archived from the original on 12 June 2020. Retrieved 8 June 2020.
Chen J (4 May 2020). "Covid-19 has shuttered labs. It could put a generation of researchers at risk". Stat. Archived from the original on 6 May 2020. Retrieved 4 May 2020.
Herper M (15 December 2020). "Inside the frantic and secretive sprint to name the Covid-19 vaccines". Stat. Archived from the original on 17 December 2020. Retrieved 19 December 2020.

tass.ru (Global: 260^th place; English: 1,423^rd place)

"В России зарегистрировали первую в мире вакцину против COVID-19 для животных" [The world's first COVID-19 vaccine for animals was registered in Russia]. TASS (in Russian). Moscow. 31 March 2021. Archived from the original on 19 May 2021. Retrieved 19 May 2021.

telegraph.co.uk (Global: 30^th place; English: 24^th place)

Gartner A, Roberts L (3 May 2020). "How close are we to a coronavirus vaccine? Latest news on UK trials". The Telegraph. ISSN 0307-1235. Archived from the original on 4 May 2020. Retrieved 3 May 2020.
Bird S (14 November 2020). "Trademark filings offer tantalising glimpse of coronavirus vaccine's name". The Daily Telegraph. Archived from the original on 12 January 2022. Retrieved 19 December 2020.

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

tga.gov.au

"TGA grants provisional determination for COVID-19 vaccine". Therapeutic Goods Administration (TGA). 9 October 2020. Archived from the original on 29 October 2020. Retrieved 25 October 2020.
"TGA grants second provisional determination for a COVID-19 vaccine". Therapeutic Goods Administration (TGA). 14 October 2020. Archived from the original on 28 October 2020. Retrieved 25 October 2020.
"TGA grants third provisional determination for a COVID-19 vaccine". Therapeutic Goods Administration (TGA). 16 November 2020. Archived from the original on 16 January 2021. Retrieved 19 December 2020.
"Comirnaty". Therapeutic Goods Administration. 25 January 2021. Archived from the original on 1 February 2021. Retrieved 25 January 2021.
"TGA provisionally approves Pfizer COVID-19 vaccine". Therapeutic Goods Administration (TGA) (Press release). 25 January 2021. Archived from the original on 26 January 2021. Retrieved 25 January 2021.
Australian Public Assessment Report for BNT162b2 (mRNA) (PDF) (Report). Therapeutic Goods Administration (TGA). Archived (PDF) from the original on 26 January 2021. Retrieved 25 January 2021.
"Elasomeran". Therapeutic Goods Administration. 24 June 2021. Archived from the original on 27 June 2021. Retrieved 18 August 2021.

ebs.tga.gov.au

"Comirnaty (BNT162b2 [mRNA]) COVID‑19 Vaccine Product Information" (PDF). Therapeutic Goods Administration (TGA). Archived from the original on 2 February 2021. Retrieved 25 January 2021.

theconversation.com (Global: 928^th place; English: 651^st place)

Grenfell R, Drew T (14 February 2020). "Here's why the WHO says a coronavirus vaccine is 18 months away". Business Insider. Archived from the original on 5 December 2020. Retrieved 11 November 2020.

theglobeandmail.com (Global: 293^rd place; English: 203^rd place)

"G20 launches initiative for health tools needed to combat the coronavirus". 25 April 2020.

theguardian.com (Global: 12^th place; English: 11^th place)

Covid news live: England drops all ‘plan B’ restrictions; Moderna begins trial of Omicron-specific booster shot Archived 29 January 2022 at the Wayback Machine The Guardian
Campbell D (16 December 2020). "138,000 people in UK receive Covid vaccine in first week". The Guardian. Archived from the original on 25 March 2022. Retrieved 18 January 2021.

thenationalnews.com (Global: 1,682^nd place; English: 1,092^nd place)

"Coronavirus: UAE authorises emergency use of vaccine for frontline workers". The National. 14 September 2020. Archived from the original on 2 January 2020. Retrieved 18 November 2020.

time.com (Global: 61^st place; English: 54^th place)

Park A (20 November 2020). "Exclusive: Pfizer CEO Discusses Submitting the First COVID-19 Vaccine Clearance Request to the FDA". Time. Archived from the original on 29 January 2021. Retrieved 20 November 2020.

vaccines.gov (Global: low place; English: low place)

"Vaccine Safety – Vaccines". vaccines.gov. US Department of Health and Human Services. Archived from the original on 22 April 2020. Retrieved 13 April 2020.

web.archive.org (Global: 1^st place; English: 1^st place)

"World Health Organization timeline – COVID-19". World Health Organization (WHO). 27 April 2020. Archived from the original on 29 April 2020. Retrieved 2 May 2020.
Weintraub R, Yadav P, Berkley S (2 April 2020). "A COVID-19 vaccine will need equitable, global distribution". Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
"COVID-19 pandemic reveals the risks of relying on private sector for life-saving vaccines, says expert". CBC Radio. 8 May 2020. Archived from the original on 13 May 2020. Retrieved 8 June 2020.
Ahmed DD (4 June 2020). "Oxford, AstraZeneca COVID-19 deal reinforces 'vaccine sovereignty'". Stat. Archived from the original on 12 June 2020. Retrieved 8 June 2020.
Grenfell R, Drew T (14 February 2020). "Here's why the WHO says a coronavirus vaccine is 18 months away". Business Insider. Archived from the original on 5 December 2020. Retrieved 11 November 2020.
Offit P (13 February 2021). "TWiV 720: With vaccines, Offit is on it". This Week in Virology Podcast. Vincent Racaniello Youtube Channel. Archived from the original on 25 May 2021. Retrieved 14 July 2021.
"Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
"WHO 'backed China's emergency use' of experimental Covid-19 vaccines". South China Morning Post. 25 September 2020. Archived from the original on 26 September 2020. Retrieved 26 September 2020.
Kramer AE (19 September 2020). "Russia Is Slow to Administer Virus Vaccine Despite Kremlin's Approval". The New York Times. ISSN 0362-4331. Archived from the original on 27 September 2020. Retrieved 28 September 2020.
"Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine". Pfizer (Press release). 20 November 2020. Archived from the original on 29 January 2021. Retrieved 20 November 2020.
Park A (20 November 2020). "Exclusive: Pfizer CEO Discusses Submitting the First COVID-19 Vaccine Clearance Request to the FDA". Time. Archived from the original on 29 January 2021. Retrieved 20 November 2020.
"Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine". Medicines & Healthcare products Regulatory Agency (MHRA). 8 December 2020. Archived from the original on 15 March 2021. Retrieved 13 December 2020.
"Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 3 December 2020. Archived from the original on 26 February 2021. Retrieved 19 December 2020.
"UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020. Archived from the original on 17 March 2021. Retrieved 2 December 2020.
Mueller B (2 December 2020). "U.K. Approves Pfizer Coronavirus Vaccine, a First in the West". The New York Times. Archived from the original on 28 January 2021. Retrieved 2 December 2020.
Roberts M (2 December 2020). "Covid Pfizer vaccine approved for use next week in UK". BBC News Online. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
"Questions and Answers: COVID-19 vaccination in the EU". European Commission. 21 December 2020. Archived from the original on 29 January 2021. Retrieved 21 December 2020.
"Bahrain second in the world to approve the Pfizer/BioNTech Covid-19 vaccine". Bahrain News Agency. 4 December 2020. Archived from the original on 17 December 2020. Retrieved 9 December 2020.
"UAE: Ministry of Health announces 86 per cent vaccine efficacy". Gulf News. Archived from the original on 24 December 2020. Retrieved 9 December 2020.
Thomas K, LaFraniere S, Weiland N, Goodnough A, Haberman M (12 December 2020). "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away". The New York Times. Archived from the original on 12 December 2020. Retrieved 12 December 2020.
"FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 17 March 2021. Retrieved 18 December 2020.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
Lovelace Jr B (19 December 2020). "FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution". CNBC. Archived from the original on 26 January 2021. Retrieved 19 December 2020.
Corum J, Zimmer C (17 December 2020). "How the Oxford-AstraZeneca Vaccine Works". The New York Times. Archived from the original on 5 January 2022. Retrieved 2 May 2021.
Tétrault-Farber M, Vasilyeva G (31 March 2021). "Russia registers world's first COVID-19 vaccine for animals". Reuters. Archived from the original on 17 December 2021. Retrieved 4 April 2021.
"В России зарегистрировали первую в мире вакцину против COVID-19 для животных" [The world's first COVID-19 vaccine for animals was registered in Russia]. TASS (in Russian). Moscow. 31 March 2021. Archived from the original on 19 May 2021. Retrieved 19 May 2021.
Abedi M (23 March 2020). "Canada to spend $192M on developing COVID-19 vaccine". Global News. Archived from the original on 9 April 2020. Retrieved 24 March 2020.
"Government of Canada funds 49 additional COVID-19 research projects – Details of the funded projects". Government of Canada. 23 March 2020. Archived from the original on 22 March 2020. Retrieved 23 March 2020.
"Government of Canada's research response to COVID-19". Government of Canada. 23 April 2020. Archived from the original on 13 May 2020. Retrieved 4 May 2020.
Aiello R (4 May 2020). "'A global challenge': PM Trudeau commits $850 million to global fight against COVID-19". CTV News. Archived from the original on 10 May 2020. Retrieved 4 May 2020.
Steenhuysen J, Eisler P, Martell A, Nebehay S (27 April 2020). "Special Report: Countries, companies risk billions in race for coronavirus vaccine". Reuters. Archived from the original on 15 May 2020. Retrieved 2 May 2020.
Sanger DE, Kirkpatrick DD, Zimmer C, Thomas K, Wee SL (2 May 2020). "With Pressure Growing, Global Race for a Vaccine Intensifies". The New York Times. ISSN 0362-4331. Archived from the original on 11 May 2020. Retrieved 2 May 2020.
Takada N, Satake M (2 May 2020). "US and China unleash wallets in race for coronavirus vaccine". Nikkei Asian Review. Archived from the original on 10 May 2020. Retrieved 3 May 2020.
Talmazan Y, Simmons K, Saravia L (18 May 2020). "China's Xi announces $2B for coronavirus response as WHO faces calls for investigation". NBC News. Archived from the original on 18 May 2020. Retrieved 18 May 2020.
Ore D (23 July 2020). "Mexico says China plans $1 billion loan to ease Latam access to virus vaccine". Reuters. Archived from the original on 25 September 2020. Retrieved 16 August 2020.
"China promises Mekong neighbours access to Chinese Covid-19 vaccine". South China Morning Post. 24 August 2020. Archived from the original on 25 September 2020. Retrieved 24 August 2020.
Morriss E (22 April 2020). "Government launches coronavirus vaccine taskforce as human clinical trials start". Pharmafield. Archived from the original on 26 June 2020. Retrieved 3 May 2020.
Gartner A, Roberts L (3 May 2020). "How close are we to a coronavirus vaccine? Latest news on UK trials". The Telegraph. ISSN 0307-1235. Archived from the original on 4 May 2020. Retrieved 3 May 2020.
"Landmark partnership announced for development of COVID-19 vaccine". University of Oxford. 30 April 2020. Archived from the original on 13 May 2020. Retrieved 3 May 2020.
Kuznia R, Polglase K, Mezzofiore G (1 May 2020). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN. Archived from the original on 13 May 2020. Retrieved 2 May 2020.
Lee CE, Welker K, Perlmutter-Gumbiner E (1 May 2020). "Health officials eyeing at least one of 14 potential coronavirus vaccines to fast-track". NBC News. Archived from the original on 11 May 2020. Retrieved 2 May 2020.
Sink J, Fabian J, Griffin R (15 May 2020). "Trump introduces 'Warp Speed' leaders to hasten COVID-19 vaccine". Bloomberg. Archived from the original on 21 May 2020. Retrieved 15 May 2020.
Griffith R, Jacobs J (3 June 2020). "White House Works With Seven Drugmakers in 'Warp Speed' Push". Bloomberg. Archived from the original on 3 June 2020. Retrieved 4 June 2020.
"Fact-checking the battle for credit over Pfizer's vaccine announcement". CNN. 10 November 2020. Archived from the original on 16 November 2020. Retrieved 13 November 2020. Pfizer is one of various vaccine manufacturers participating in Operation Warp Speed as a supplier of a potential COVID-19 vaccine," Castillo said in an email. "While Pfizer did reach an advanced purchase agreement with the U.S. government, the company did not accept (Biomedical Advanced Research and Development Authority) funding for the research and development process. All the investment for R&D was made by Pfizer at risk. Dr. Jansen was emphasizing that last point.
McGrail S (15 April 2020). "Sanofi, GSK partner to develop adjuvanted COVID-19 vaccine". PharmaNewsIntelligence. Archived from the original on 9 May 2020. Retrieved 4 May 2020.
Blankenship K (4 June 2020). "AstraZeneca unveils massive $750M deal in effort to produce billions of COVID-19 shots". FiercePharma. Archived from the original on 10 June 2020. Retrieved 8 June 2020.
Schmidt C (1 June 2020). "Genetic Engineering Could Make a COVID-19 Vaccine in Months Rather Than Years". Scientific American. Archived from the original on 11 October 2020. Retrieved 26 August 2020.
Gates B (30 April 2020). "The vaccine race explained: What you need to know about the COVID-19 vaccine". The Gates Notes. Archived from the original on 14 May 2020. Retrieved 2 May 2020.
Fox C, Kelion L (16 July 2020). "Russian spies 'target coronavirus vaccine'". BBC News. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
Coronavirus: North Korea and Russia hackers 'targeting vaccine' Archived 17 December 2021 at the Wayback Machine, (13 November 2020).
North Korea accused of hacking Pfizer for Covid-19 vaccine data Archived 24 April 2022 at the Wayback Machine, BBC News (16 February 2021).
"Public statement for collaboration on COVID-19 vaccine development". World Health Organization (WHO). 13 April 2020. Archived from the original on 20 April 2020. Retrieved 20 April 2020.
"Clinical Development Success Rates 2006–2015" (PDF). BIO Industry Analysis. June 2016. Archived (PDF) from the original on 12 September 2019. Retrieved 23 March 2020.
Chen J (4 May 2020). "Covid-19 has shuttered labs. It could put a generation of researchers at risk". Stat. Archived from the original on 6 May 2020. Retrieved 4 May 2020.
Hackethal V (16 March 2021). "Why ADE Hasn't Been a Problem With COVID Vaccines". www.medpagetoday.com. Archived from the original on 25 June 2021. Retrieved 1 July 2021.
"Draft landscape of COVID 19 candidate vaccines". World Health Organization (WHO). 10 December 2020. Archived from the original on 30 April 2020. Retrieved 11 December 2020.
"An international randomised trial of candidate vaccines against COVID-19: Outline of Solidarity vaccine trial" (PDF). World Health Organization (WHO). 9 April 2020. Archived (PDF) from the original on 12 May 2020. Retrieved 9 May 2020.
"Vaccine Safety – Vaccines". vaccines.gov. US Department of Health and Human Services. Archived from the original on 22 April 2020. Retrieved 13 April 2020.
"The drug development process". U.S. Food and Drug Administration (FDA). 4 January 2018. Archived from the original on 22 February 2020. Retrieved 12 April 2020.
"How flu vaccine effectiveness and efficacy are measured". Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, US Department of Health and Human Services. 29 January 2016. Archived from the original on 7 May 2020. Retrieved 6 May 2020.
"Principles of epidemiology, Section 8: Concepts of disease occurrence". Centers for Disease Control and Prevention, Center for Surveillance, Epidemiology, and Laboratory Services, US Department of Health and Human Services. 18 May 2012. Archived from the original on 6 April 2020. Retrieved 6 May 2020.
AstraZeneca (12 April 2021). "A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19". Iqvia Pty Ltd. Archived from the original on 23 August 2020. Retrieved 11 June 2021.
Covid news live: England drops all ‘plan B’ restrictions; Moderna begins trial of Omicron-specific booster shot Archived 29 January 2022 at the Wayback Machine The Guardian
Howard J, Stracqualursi V (18 June 2020). "Fauci warns of 'anti-science bias' being a problem in US". CNN. Archived from the original on 21 June 2020. Retrieved 21 June 2020.
"Adaptive designs for clinical trials of drugs and biologics: Guidance for industry" (PDF). U.S. Food and Drug Administration (FDA). 1 November 2019. Archived from the original on 13 December 2019. Retrieved 3 April 2020.
"Key criteria for the ethical acceptability of COVID-19 human challenge studies" (PDF). World Health Organization (WHO). 6 May 2020. Archived (PDF) from the original on 8 May 2020. Retrieved 12 May 2020.
"WHO publishes Emergency Use Listing procedure and roadmap to make new medical products more readily available during health emergencies" (Press release). World Health Organization (WHO). 9 January 2020. Archived from the original on 29 September 2020. Retrieved 23 August 2020.
"Vaccines: The Emergency Authorisation Procedure". European Medicines Agency. 2020. Archived from the original on 24 September 2020. Retrieved 21 August 2020.
Byrne J (19 October 2020). "Moderna COVID-19 vaccine under rolling review process in Canada, EU". BioPharma-Reporter.com, William Reed Business Media Ltd. Archived from the original on 25 February 2021. Retrieved 25 November 2020.
Dangerfield K (20 November 2020). "Pfizer files for emergency use of coronavirus vaccine in U.S. – what about in Canada?". Global News. Archived from the original on 25 January 2021. Retrieved 25 November 2020.
"Coronavirus: UAE authorises emergency use of vaccine for frontline workers". The National. 14 September 2020. Archived from the original on 2 January 2020. Retrieved 18 November 2020.
Barrington L (3 November 2020). "Bahrain latest country to vaccinate frontline workers with COVID-19 shot". Reuters. Archived from the original on 30 December 2021. Retrieved 18 November 2020.
"Emergency Use Authorization for Vaccines Explained". U.S. Food and Drug Administration (FDA). 20 November 2020. Archived from the original on 20 November 2020. Retrieved 20 November 2020. This article incorporates text from this source, which is in the public domain.
Healthcare G (2 July 2020). "FDA may be risk-averse to grant emergency use for a Covid-19 vaccine; political pressure and hazy EUA standards are factors". Clinical Trials Arena. ClinicalTrials Arena, Verdict Media, Ltd. Archived from the original on 22 July 2020. Retrieved 22 August 2020.
Hoffman J (18 July 2020). "Mistrust of a coronavirus vaccine could imperil widespread immunity". The New York Times. Archived from the original on 27 September 2020. Retrieved 23 August 2020.
"Biopharma Leaders Unite to Stand with Science" (Press release). 8 September 2020. Archived from the original on 1 January 2021. Retrieved 31 December 2020 – via Business Wire.
"Covid-19 vaccine: Margaret Keenan 'so privileged' to get first jab". BBC News Online. 8 December 2020. Archived from the original on 8 December 2020. Retrieved 8 December 2020.
Mueller B (8 December 2020). "As U.K. Begins Vaccinations, a Glimpse of Life After Covid". The New York Times. Archived from the original on 14 December 2020. Retrieved 20 December 2020.
"Covid: Russia begins vaccinations in Moscow". BBC News Online. 5 December 2020. Archived from the original on 1 June 2022. Retrieved 18 January 2021.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (December 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (50): 1922–24. doi:10.15585/mmwr.mm6950e2. PMC 7745957. PMID 33332292. Archived (PDF) from the original on 19 December 2020. Retrieved 18 January 2021.
"Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 19 December 2020. Archived from the original on 10 January 2021. Retrieved 19 December 2020.
"COVID-19: Switzerland can start vaccinating vulnerable groups already in December" (Press release). Swiss Federal Office of Public Health. 19 December 2020. Archived from the original on 9 January 2021. Retrieved 19 December 2020.
Pralong J (23 December 2020). "La piqûre de l'espoir pratiquée à Lucerne". Heidi.news. Archived from the original on 10 January 2021. Retrieved 23 December 2020.
Campbell D (16 December 2020). "138,000 people in UK receive Covid vaccine in first week". The Guardian. Archived from the original on 25 March 2022. Retrieved 18 January 2021.
Herper M (15 December 2020). "Inside the frantic and secretive sprint to name the Covid-19 vaccines". Stat. Archived from the original on 17 December 2020. Retrieved 19 December 2020.
"Moderna Applies for Emergency F.D.A. Approval for Its Coronavirus Vaccine". The New York Times. 30 November 2020. Archived from the original on 30 November 2020. Retrieved 30 November 2020.
"Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization". Moderna, Inc. (Press release). 30 November 2020. Archived from the original on 30 November 2020. Retrieved 30 November 2020.
"Oxford University/AstraZeneca vaccine authorised by UK medicines regulator". Gov.uk. Department of Health and Social Care. 30 December 2020. Archived from the original on 16 March 2021. Retrieved 30 December 2020.
"Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Archived from the original on 9 March 2021. Retrieved 4 January 2021.
"Conditions of Authorisation for COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Archived from the original on 18 February 2021. Retrieved 4 January 2021.
"TGA grants provisional determination for COVID-19 vaccine". Therapeutic Goods Administration (TGA). 9 October 2020. Archived from the original on 29 October 2020. Retrieved 25 October 2020.
"TGA grants second provisional determination for a COVID-19 vaccine". Therapeutic Goods Administration (TGA). 14 October 2020. Archived from the original on 28 October 2020. Retrieved 25 October 2020.
"TGA grants third provisional determination for a COVID-19 vaccine". Therapeutic Goods Administration (TGA). 16 November 2020. Archived from the original on 16 January 2021. Retrieved 19 December 2020.
"Comirnaty". Therapeutic Goods Administration. 25 January 2021. Archived from the original on 1 February 2021. Retrieved 25 January 2021.
"TGA provisionally approves Pfizer COVID-19 vaccine". Therapeutic Goods Administration (TGA) (Press release). 25 January 2021. Archived from the original on 26 January 2021. Retrieved 25 January 2021.
"Comirnaty (BNT162b2 [mRNA]) COVID‑19 Vaccine Product Information" (PDF). Therapeutic Goods Administration (TGA). Archived from the original on 2 February 2021. Retrieved 25 January 2021.
Australian Public Assessment Report for BNT162b2 (mRNA) (PDF) (Report). Therapeutic Goods Administration (TGA). Archived (PDF) from the original on 26 January 2021. Retrieved 25 January 2021.
"Elasomeran". Therapeutic Goods Administration. 24 June 2021. Archived from the original on 27 June 2021. Retrieved 18 August 2021.
"EMA starts first rolling review of a COVID-19 vaccine in the EU" (Press release). European Medicines Agency (EMA). 1 October 2020. Archived from the original on 1 October 2020. Retrieved 1 October 2020.
"COVID-19 vaccines: key facts". European Medicines Agency (EMA). 14 September 2020. Archived from the original on 7 October 2020. Retrieved 1 October 2020.
"EMA starts second rolling review of a COVID-19 vaccine" (Press release). European Medicines Agency (EMA). 5 October 2020. Archived from the original on 6 October 2020. Retrieved 6 October 2020.
"Update on rolling review of AstraZeneca's COVID-19 vaccine" (Press release). European Medicines Agency (EMA). 30 December 2020. Archived from the original on 30 December 2020. Retrieved 30 December 2020.
"EMA publishes safety monitoring plan and guidance on risk management planning for COVID-19 vaccines" (Press release). European Medicines Agency (EMA). 13 November 2020. Archived from the original on 13 November 2020. Retrieved 13 November 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"EMA considerations on COVID-19 vaccine approval". European Medicines Agency (EMA). 19 November 2020. Archived from the original on 19 November 2020. Retrieved 19 November 2020.
"EMA starts rolling review of mRNA COVID-19 vaccine by Moderna Biotech Spain, S.L." (Press release). European Medicines Agency (EMA). 16 November 2020. Archived from the original on 16 November 2020. Retrieved 16 November 2020.
"EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine" (Press release). European Medicines Agency (EMA). 1 December 2020. Archived from the original on 1 December 2020. Retrieved 1 December 2020.
"EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2" (Press release). European Medicines Agency (EMA). 1 December 2020. Archived from the original on 1 December 2020. Retrieved 1 December 2020.
"Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application" (Press release). European Medicines Agency (EMA). 15 December 2020. Archived from the original on 15 December 2020. Retrieved 15 December 2020.
"Update on assessment of marketing authorisation application for Moderna's mRNA-1273 COVID-19 vaccine" (Press release). European Medicines Agency (EMA). 17 December 2020. Archived from the original on 17 December 2020. Retrieved 17 December 2020.
"EMA starts rolling review of Janssen's COVID-19 vaccine Ad26.COV2.S" (Press release). European Medicines Agency (EMA). 1 December 2020. Archived from the original on 8 January 2021. Retrieved 1 December 2020.
"EMA recommends first COVID-19 vaccine for authorisation in the EU" (Press release). European Medicines Agency (EMA). 21 December 2020. Archived from the original on 30 January 2021. Retrieved 21 December 2020.
"Comirnaty EPAR". European Medicines Agency (EMA). 21 December 2020. Archived from the original on 24 January 2022. Retrieved 23 December 2020.
"Statement by President von der Leyen on the marketing authorisation of the BioNTech-Pfizer vaccine against COVID-19". European Commission. Archived from the original on 11 January 2021. Retrieved 21 December 2020.
"Comirnaty". Union Register of medicinal products. Archived from the original on 24 January 2021. Retrieved 29 January 2021.
"COVID-19 Vaccine Moderna EPAR". European Medicines Agency (EMA). 4 January 2021. Archived from the original on 12 March 2021. Retrieved 20 January 2021.
"EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU" (Press release). European Medicines Agency. 6 January 2021. Archived from the original on 17 March 2021. Retrieved 6 January 2021.
"European Commission authorises second safe and effective vaccine against COVID-19". European Commission (Press release). Archived from the original on 20 January 2021. Retrieved 6 January 2021.
"COVID-19 Vaccine Moderna". Union Register of medicinal products. Archived from the original on 24 January 2021. Retrieved 14 January 2021.
"EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca". European Medicines Agency (EMA). 12 January 2021. Archived from the original on 30 March 2021. Retrieved 12 January 2021.
"COVID-19 Vaccine AstraZeneca". European Medicines Agency (EMA). 28 January 2021. Archived from the original on 16 February 2021. Retrieved 29 January 2021.
"EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU" (Press release). European Medicines Agency (EMA). 29 January 2021. Archived from the original on 9 February 2021. Retrieved 29 January 2021.
"European Commission authorises third safe and effective vaccine against COVID-19". European Commission (Press release). Archived from the original on 10 February 2021. Retrieved 29 January 2021.
"COVID-19 Vaccine AstraZeneca". Union Register of medicinal products. Archived from the original on 26 March 2021. Retrieved 29 January 2021.
"EMA starts rolling review of Novavax's COVID-19 vaccine (NVX-CoV2373)". European Medicines Agency (EMA). 3 February 2021. Archived from the original on 2 July 2021. Retrieved 3 February 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"EMA starts rolling review of CureVac's COVID-19 vaccine (CVnCoV)" (Press release). European Medicines Agency (EMA). 11 February 2021. Archived from the original on 12 February 2021. Retrieved 12 February 2021.
"EMA preparing guidance to tackle COVID-19 variants" (Press release). European Medicines Agency (EMA). 10 February 2021. Archived from the original on 15 February 2021. Retrieved 10 February 2021.
"EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen". European Medicines Agency (EMA). 16 February 2021. Archived from the original on 16 February 2021. Retrieved 16 February 2021.
"COVID-19 Vaccine Janssen EPAR". European Medicines Agency (EMA). 5 March 2021. Archived from the original on 15 March 2021. Retrieved 11 July 2021.
"EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU". European Medicines Agency (EMA) (Press release). 11 March 2021. Archived from the original on 11 March 2021. Retrieved 11 July 2021.
"European Commission authorises fourth safe and effective vaccine against COVID-19". European Commission (Press release). Archived from the original on 25 August 2020. Retrieved 11 July 2021.
"EMA starts rolling review of the Sputnik V COVID-19 vaccine" (Press release). European Medicines Agency (EMA). 4 March 2021. Archived from the original on 4 March 2021. Retrieved 4 March 2021.
"EMA starts evaluating use of COVID-19 vaccine Comirnaty in young people aged 12 to 15". European Medicines Agency (EMA) (Press release). 3 May 2021. Archived from the original on 7 May 2021. Retrieved 7 May 2021.
"EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated". European Medicines Agency (EMA) (Press release). 4 May 2021. Archived from the original on 4 May 2021. Retrieved 7 May 2021.

who.int (Global: 195^th place; English: 302^nd place)

who.int

"World Health Organization timeline – COVID-19". World Health Organization (WHO). 27 April 2020. Archived from the original on 29 April 2020. Retrieved 2 May 2020.
"Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
"Access to COVID-19 Tools (ACT) Accelerator" (PDF). World Health Organization (WHO). 24 April 2020.
"Public statement for collaboration on COVID-19 vaccine development". World Health Organization (WHO). 13 April 2020. Archived from the original on 20 April 2020. Retrieved 20 April 2020.
"Draft landscape of COVID 19 candidate vaccines". World Health Organization (WHO). 10 December 2020. Archived from the original on 30 April 2020. Retrieved 11 December 2020.
"An international randomised trial of candidate vaccines against COVID-19: Outline of Solidarity vaccine trial" (PDF). World Health Organization (WHO). 9 April 2020. Archived (PDF) from the original on 12 May 2020. Retrieved 9 May 2020.
"WHO publishes Emergency Use Listing procedure and roadmap to make new medical products more readily available during health emergencies" (Press release). World Health Organization (WHO). 9 January 2020. Archived from the original on 29 September 2020. Retrieved 23 August 2020.

apps.who.int

"Key criteria for the ethical acceptability of COVID-19 human challenge studies" (PDF). World Health Organization (WHO). 6 May 2020. Archived (PDF) from the original on 8 May 2020. Retrieved 12 May 2020.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Weintraub R, Yadav P, Berkley S (2 April 2020). "A COVID-19 vaccine will need equitable, global distribution". Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
Kramer AE (19 September 2020). "Russia Is Slow to Administer Virus Vaccine Despite Kremlin's Approval". The New York Times. ISSN 0362-4331. Archived from the original on 27 September 2020. Retrieved 28 September 2020.
Moon S, Armstrong J, Hutler B, Upshur R, Katz R, Atuire C, Bhan A, Emanuel E, Faden R, Ghimire P, Greco D (29 January 2022). "Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability". The Lancet. 399 (10323): 487–494. doi:10.1016/S0140-6736(21)02344-8. ISSN 0140-6736. PMC 8797025. PMID 34902308.
Sanger DE, Kirkpatrick DD, Zimmer C, Thomas K, Wee SL (2 May 2020). "With Pressure Growing, Global Race for a Vaccine Intensifies". The New York Times. ISSN 0362-4331. Archived from the original on 11 May 2020. Retrieved 2 May 2020.
Gartner A, Roberts L (3 May 2020). "How close are we to a coronavirus vaccine? Latest news on UK trials". The Telegraph. ISSN 0307-1235. Archived from the original on 4 May 2020. Retrieved 3 May 2020.
Cohen J (15 May 2020). "U.S. 'Warp Speed' vaccine effort comes out of the shadows". Science. 368 (6492): 692–93. Bibcode:2020Sci...368..692C. doi:10.1126/science.368.6492.692. ISSN 0036-8075. PMID 32409451.
Cohen J (4 June 2020). "Top U.S. scientists left out of White House selection of COVID-19 vaccine short list". Science. doi:10.1126/science.abd1719. ISSN 0036-8075.
Pandamooz S, Jurek B, Meinung CP, Baharvand Z, Sahebi Shahem-abadi A, Haerteis S, Miyan JA, Downing J, Dianatpour M, Borhani-Haghighi A, Salehi MS (6 January 2022). "Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments". Annual Review of Pharmacology and Toxicology. 62 (1): 25–53. doi:10.1146/annurev-pharmtox-121120-012309. ISSN 0362-1642. PMID 33606962. S2CID 231970935.
Haynes BF, Corey L, Fernandes P, Gilbert PB, Hotez PJ, Rao S, Santos MR, Schuitemaker H, Watson M, Arvin A (4 November 2020). "Prospects for a safe COVID-19 vaccine". Science Translational Medicine. 12 (568) eabe0948. doi:10.1126/scitranslmed.abe0948. ISSN 1946-6242. PMID 33077678. S2CID 224809822.
Cavaleri M, Enzmann H, Straus S, Cooke E (January 2021). "The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines". Lancet. 397 (10272): 355–357. doi:10.1016/s0140-6736(21)00085-4. ISSN 0140-6736. PMC 7833511. PMID 33453149.

youtube.com (Global: 9^th place; English: 13^th place)

Offit P (13 February 2021). "TWiV 720: With vaccines, Offit is on it". This Week in Virology Podcast. Vincent Racaniello Youtube Channel. Archived from the original on 25 May 2021. Retrieved 14 July 2021.

History of COVID-19 vaccine development (English Wikipedia)

admin.ch (Global: 279th place; English: 551st place)

bag.admin.ch

apnews.com (Global: 129th place; English: 89th place)

archive-it.org (Global: 910th place; English: 593rd place)

wayback.archive-it.org

bbc.com (Global: 20th place; English: 30th place)

bio.org (Global: low place; English: low place)

biopharma-reporter.com (Global: low place; English: low place)

bloomberg.com (Global: 99th place; English: 77th place)

bna.bh (Global: low place; English: low place)

businesswire.com (Global: 615th place; English: 407th place)

canada.ca (Global: 1,712th place; English: 1,063rd place)

cbc.ca (Global: 115th place; English: 82nd place)

cdc.gov (Global: 218th place; English: 212th place)

clinicaltrials.gov (Global: 5,225th place; English: 4,062nd place)

clinicaltrialsarena.com (Global: low place; English: low place)

cnbc.com (Global: 220th place; English: 155th place)

cnn.com (Global: 28th place; English: 26th place)

cnn.com

edition.cnn.com

ctvnews.ca (Global: 768th place; English: 482nd place)

doi.org (Global: 2nd place; English: 2nd place)

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

ec.europa.eu

fda.gov (Global: 447th place; English: 338th place)

fiercepharma.com (Global: low place; English: 8,921st place)

gatesnotes.com (Global: low place; English: low place)

ghostarchive.org (Global: 32nd place; English: 21st place)

globalnews.ca (Global: 985th place; English: 583rd place)

gov.uk (Global: 432nd place; English: 278th place)

gulfnews.com (Global: 765th place; English: 523rd place)

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

hbr.org (Global: 2,754th place; English: 1,686th place)

heidi.news (Global: low place; English: low place)

medpagetoday.com (Global: 9,274th place; English: 5,856th place)

modernatx.com (Global: low place; English: low place)

investors.modernatx.com

nationalpost.com (Global: 818th place; English: 524th place)

nbcnews.com (Global: 137th place; English: 101st place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

nikkei.com (Global: 211th place; English: 915th place)

asia.nikkei.com

nytimes.com (Global: 7th place; English: 7th place)

ox.ac.uk (Global: 613th place; English: 456th place)

pfizer.com (Global: low place; English: low place)

pharmafield.co.uk (Global: low place; English: low place)

pharmanewsintel.com (Global: low place; English: low place)

reuters.com (Global: 49th place; English: 47th place)

scientificamerican.com (Global: 896th place; English: 674th place)

scmp.com (Global: 362nd place; English: 245th place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

statnews.com (Global: 8,771st place; English: 5,253rd place)

tass.ru (Global: 260th place; English: 1,423rd place)

telegraph.co.uk (Global: 30th place; English: 24th place)

tga.gov.au (Global: 3,984th place; English: 2,622nd place)

tga.gov.au

ebs.tga.gov.au

theconversation.com (Global: 928th place; English: 651st place)

theglobeandmail.com (Global: 293rd place; English: 203rd place)

theguardian.com (Global: 12th place; English: 11th place)

thenationalnews.com (Global: 1,682nd place; English: 1,092nd place)

time.com (Global: 61st place; English: 54th place)

vaccines.gov (Global: low place; English: low place)

web.archive.org (Global: 1st place; English: 1st place)

who.int (Global: 195th place; English: 302nd place)

who.int

apps.who.int

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

youtube.com (Global: 9th place; English: 13th place)

admin.ch (Global: 279^th place; English: 551^st place)

apnews.com (Global: 129^th place; English: 89^th place)

archive-it.org (Global: 910^th place; English: 593^rd place)

bbc.com (Global: 20^th place; English: 30^th place)

bloomberg.com (Global: 99^th place; English: 77^th place)

businesswire.com (Global: 615^th place; English: 407^th place)

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

cbc.ca (Global: 115^th place; English: 82^nd place)

cdc.gov (Global: 218^th place; English: 212^th place)

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

cnbc.com (Global: 220^th place; English: 155^th place)

cnn.com (Global: 28^th place; English: 26^th place)

ctvnews.ca (Global: 768^th place; English: 482^nd place)

doi.org (Global: 2^nd place; English: 2^nd place)

europa.eu (Global: 68^th place; English: 117^th place)

fda.gov (Global: 447^th place; English: 338^th place)

fiercepharma.com (Global: low place; English: 8,921^st place)

ghostarchive.org (Global: 32^nd place; English: 21^st place)

globalnews.ca (Global: 985^th place; English: 583^rd place)

gov.uk (Global: 432^nd place; English: 278^th place)

gulfnews.com (Global: 765^th place; English: 523^rd place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

hbr.org (Global: 2,754^th place; English: 1,686^th place)

medpagetoday.com (Global: 9,274^th place; English: 5,856^th place)

nationalpost.com (Global: 818^th place; English: 524^th place)

nbcnews.com (Global: 137^th place; English: 101^st place)

nih.gov (Global: 4^th place; English: 4^th place)

nikkei.com (Global: 211^th place; English: 915^th place)

nytimes.com (Global: 7^th place; English: 7^th place)

ox.ac.uk (Global: 613^th place; English: 456^th place)

reuters.com (Global: 49^th place; English: 47^th place)

scientificamerican.com (Global: 896^th place; English: 674^th place)

scmp.com (Global: 362^nd place; English: 245^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

statnews.com (Global: 8,771^st place; English: 5,253^rd place)

tass.ru (Global: 260^th place; English: 1,423^rd place)

telegraph.co.uk (Global: 30^th place; English: 24^th place)

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

theconversation.com (Global: 928^th place; English: 651^st place)

theglobeandmail.com (Global: 293^rd place; English: 203^rd place)

theguardian.com (Global: 12^th place; English: 11^th place)

thenationalnews.com (Global: 1,682^nd place; English: 1,092^nd place)

time.com (Global: 61^st place; English: 54^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

who.int (Global: 195^th place; English: 302^nd place)

worldcat.org (Global: 5^th place; English: 5^th place)

youtube.com (Global: 9^th place; English: 13^th place)